Georg Kojda
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Georg Kojda has a total of 122 co-authors. Here are the top co-authors by number of shared publications:
Tatsiana Suvorava
Institute of Pharmacology, University Hospital, Heinrich Heine University, Düsseldorf, Germany
13 shared publicationsAndreas Hacker
Institut fuer Pharmakologie und Klinische Pharmakologie, Heinrich-Heine-Universitaet, Duesseldorf, Germany
6 shared publicationsEike Noack
Institut für Pharmakologie und Klinische Pharmakologie, Medizinische Einrichtungen, Heinrich‐Heine‐Universität, 40225 Düsseldorf, Universität Leipzig, Liebigstrasse 27, 04103 Leipzig, Germany
6 shared publicationsMartina Weber
Division of Cardiology, Emory University School of Medicine , Atlanta, Georgia
6 shared publicationsMurat Bas
Otorhinolaryngology Department, University Hospital Rechts der Isar, Munich Technical University, Munich, Germany
5 shared publicationsVu Thao-Vi Dao
5 shared publications
Latest Publications
- Open Access
- 12 November 2026
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 205
Contribution of angiotensin receptor type II to dermal extravasation caused by bradykinin in mice: Implications for sartan-induced angioedema
- 12 November 2026
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 205
Open AccessContribution of angiotensin receptor type II to dermal extravasation caused by bradykinin in mice: Implications for sartan-induced angioedema
- Open Access
- 8 September 2023
- Published by MDPI AG in Drugs and Drug Candidates
- Vol. 2 (3) , 708-727
Bradykinin-Mediated Angioedema Induced by Commonly Used Cardiovascular Drugs
ACE inhibitors, sartans, and sacubitril are among the most important drugs for the prevention of cardiovascular mortality and morbidity. At the same time, they are known to cause non-allergic bradykinin-mediated angioedema, a potentially fatal swelling of the mucosa and/or submucosa and deeper skin without signs of urticaria or pruritus, occurring mainly in the head and neck region. In contrast with hereditary angioedema, which is also mediated by bradykinin, angioedema triggered by these drugs is by far the most common subtype of non-allergic angioedema. The molecular mechanisms underlying this type of angioedema, which are discussed here, are not yet sufficiently understood. There are a number of approved drugs for the prevention and treatment of acute attacks of hereditary angioedema. These include inhibitors of bradykinin synthesis that act as kallkrein inhibitors, such as the parenterally applied plasma pool, and recombinant C1 esterase inhibitor, ecallantide, lanadelumab, and the orally available berotralstat, as well as the bradykinin receptor type 2 antagonist icatibant. In contrast, no diagnostic tools, guidelines, or treatments have yet been approved for the diagnosis and treatment of acute non-allergic drug-induced angioedema, although it is more common and can take life-threatening courses. Approved specific drugs and a structured diagnostic workflow are needed for this emergency diagnosis.
- 8 September 2023
- Published by MDPI AG in Drugs and Drug Candidates
- Vol. 2 (3) , 708-727
Open AccessBradykinin-Mediated Angioedema Induced by Commonly Used Cardiovascular Drugs
ACE inhibitors, sartans, and sacubitril are among the most important drugs for the prevention of cardiovascular mortality and morbidity. At the same time, they are known to cause non-allergic bradykinin-mediated angioedema, a potentially fatal swelling of the mucosa and/or submucosa and deeper skin without signs of urticaria or pruritus, occurring mainly in the head and neck region. In contrast with hereditary angioedema, which is also mediated by bradykinin, angioedema triggered by these drugs is by far the most common subtype of non-allergic angioedema. The molecular mechanisms underlying this type of angioedema, which are discussed here, are not yet sufficiently understood. There are a number of approved drugs for the prevention and treatment of acute attacks of hereditary angioedema. These include inhibitors of bradykinin synthesis that act as kallkrein inhibitors, such as the parenterally applied plasma pool, and recombinant C1 esterase inhibitor, ecallantide, lanadelumab, and the orally available berotralstat, as well as the bradykinin receptor type 2 antagonist icatibant. In contrast, no diagnostic tools, guidelines, or treatments have yet been approved for the diagnosis and treatment of acute non-allergic drug-induced angioedema, although it is more common and can take life-threatening courses. Approved specific drugs and a structured diagnostic workflow are needed for this emergency diagnosis.
- 19 September 2022
- Published by Elsevier in Biochemical Pharmacology
- Vol. 205, 115256
Alterations in endothelial nitric oxide synthase activity and their relevance to blood pressure
- 19 September 2022
- Published by Elsevier in Biochemical Pharmacology
- Vol. 205, 115256
Alterations in endothelial nitric oxide synthase activity and their relevance to blood pressure
- Open Access
- 5 March 2022
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 148, 112786
Contribution of cyclooxygenase-1-dependent prostacyclin synthesis to bradykinin-induced dermal extravasation
- 5 March 2022
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 148, 112786
Open AccessContribution of cyclooxygenase-1-dependent prostacyclin synthesis to bradykinin-induced dermal extravasation
- Open Access
- 1 March 2020
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 123, 109797
Cyclooxygenase activity in bradykinin-induced dermal extravasation. A study in mice and humans
- 1 March 2020
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 123, 109797
Open AccessCyclooxygenase activity in bradykinin-induced dermal extravasation. A study in mice and humans
- Open Access
- 21 February 2018
- Published by Wiley in British Journal of Pharmacology
- Vol. 175 (10) , 1607-1620
The role of bradykinin receptor type 2 in spontaneous extravasation in mice skin: implications for non‐allergic angio‐oedema
Background and Purpose: Non‐allergic angio‐oedema is a life‐threatening disease mediated by activation of bradykinin type 2 receptors (B2 receptors). The aim of this study was to investigate whether activation of B2 receptors by endogenous bradykinin contributes to physiological extravasation. This may shed new light on the assumption that treatment with an angiotensin converting enzyme inhibitor (ACEi) results in an alteration in the vascular barrier function predisposing to non‐allergic angio‐oedema.Experimental Approach: We generated a new transgenic mouse model characterized by endothelium‐specific overexpression of the B2 receptor (B2tg) and established a non‐invasive two‐photon laser microscopy approach to measure the kinetics of spontaneous extravasation in vivo. The B2tg mice showed normal morphology and litter size as compared with their transgene‐negative littermates (B2n).Key Results: Overexpression of B2 receptors was functional in conductance vessels and resistance vessels as evidenced by B2 receptor‐mediated aortic dilation to bradykinin in presence of non‐specific COX inhibitor diclofenac and by significant hypotension in B2tg respectively. Measurement of dermal extravasation by Miles assay showed that bradykinin induced extravasation was significantly increased in B2tg as compared with B2n. However, neither endothelial overexpression of B2 receptors nor treatment with the ACEi moexipril or B2 antagonist icatibant had any effect on spontaneous extravasation measured by two‐photon laser microscopy.Conclusions and Implications: Activation of B2 receptors does not appear to be involved in spontaneous extravasation. Therefore, the assumption that treatment with an ACEi results in an alteration in the physiological vascular barrier function predisposing to non‐allergic angio‐oedema is not supported by our findings.
- 21 February 2018
- Published by Wiley in British Journal of Pharmacology
- Vol. 175 (10) , 1607-1620
Open AccessThe role of bradykinin receptor type 2 in spontaneous extravasation in mice skin: implications for non‐allergic angio‐oedema
Background and Purpose: Non‐allergic angio‐oedema is a life‐threatening disease mediated by activation of bradykinin type 2 receptors (B2 receptors). The aim of this study was to investigate whether activation of B2 receptors by endogenous bradykinin contributes to physiological extravasation. This may shed new light on the assumption that treatment with an angiotensin converting enzyme inhibitor (ACEi) results in an alteration in the vascular barrier function predisposing to non‐allergic angio‐oedema.Experimental Approach: We generated a new transgenic mouse model characterized by endothelium‐specific overexpression of the B2 receptor (B2tg) and established a non‐invasive two‐photon laser microscopy approach to measure the kinetics of spontaneous extravasation in vivo. The B2tg mice showed normal morphology and litter size as compared with their transgene‐negative littermates (B2n).Key Results: Overexpression of B2 receptors was functional in conductance vessels and resistance vessels as evidenced by B2 receptor‐mediated aortic dilation to bradykinin in presence of non‐specific COX inhibitor diclofenac and by significant hypotension in B2tg respectively. Measurement of dermal extravasation by Miles assay showed that bradykinin induced extravasation was significantly increased in B2tg as compared with B2n. However, neither endothelial overexpression of B2 receptors nor treatment with the ACEi moexipril or B2 antagonist icatibant had any effect on spontaneous extravasation measured by two‐photon laser microscopy.Conclusions and Implications: Activation of B2 receptors does not appear to be involved in spontaneous extravasation. Therefore, the assumption that treatment with an ACEi results in an alteration in the physiological vascular barrier function predisposing to non‐allergic angio‐oedema is not supported by our findings.
- 1 July 2016
- Published by Elsevier in Biochemical Pharmacology
- Vol. 112, 24-36
Nitric oxide up-regulates endothelial expression of angiotensin II type 2 receptors
- 1 July 2016
- Published by Elsevier in Biochemical Pharmacology
- Vol. 112, 24-36
Nitric oxide up-regulates endothelial expression of angiotensin II type 2 receptors
- 1 February 2016
- Vol. 14 (1) , 86-92
Preservation of Endothelial and Smooth Muscle Function of Human Saphenous Vein Transplants.
Methods for conservation and preservation of vascular grafts are often controversially discussed. Furthermore, immunologic monitoring or immunotherapy for allogeneic graft is not considered necessary in many cases. The present study was initiated to examine the cellular vitality and functional efficiency of vein transplant during preservation. Twenty-seven human vein segments (vena saphena magna) were stored after explant in University of Wisconsin solution or histidine-tryptophan-ketoglutarate solution at 4 °C. After 3, 24, 48, 72, and 96 hours, vein functionality was tested. Ring segments were fixed by triangles in Krebs-Henseleit buffer. Contractile function was measured after addition of potassium chloride solution (80 mM) and phenylephrine (0.2, 2, or 20 μM). To investigate endothelium-dependent vasorelaxation, 1 μM acetylcholine was added. Of 27 segments, 5 showed endothelium-dependent relaxation. Vasorelaxation continued for up to 48 hours after administration of acetylcholine in University of Wisconsin solution and for up to 24 hours in histidine-tryptophane-ketoglutarate solution. At 48 hours, potassium chloride solution-induced vasocontraction was 17% more effective than phenylephrine in University of Wisconsin solution. University of Wisconsin solution was significantly more effective than histidine-tryptophane-ketoglutarate solution in terms of preservation of phenylephrine (0.2, 2 μM)-induced vasocontraction. Phenylephrine (2 μM)-induced contraction was retained in University of Wisconsin solution after 24 hours by 81% and after 48 hours by 55%, with comparable results in histidine-tryptophane-ketoglutarate solution of only 62% and 34% after 24 and 48 hours. At 48 hours, human saphenous vein transplants had better endothelium and smooth muscle function when preserved in University of Wisconsin solution versus histidine-tryptophane-ketoglutarate solution.
- 1 February 2016
- Vol. 14 (1) , 86-92
Preservation of Endothelial and Smooth Muscle Function of Human Saphenous Vein Transplants.
Methods for conservation and preservation of vascular grafts are often controversially discussed. Furthermore, immunologic monitoring or immunotherapy for allogeneic graft is not considered necessary in many cases. The present study was initiated to examine the cellular vitality and functional efficiency of vein transplant during preservation. Twenty-seven human vein segments (vena saphena magna) were stored after explant in University of Wisconsin solution or histidine-tryptophan-ketoglutarate solution at 4 °C. After 3, 24, 48, 72, and 96 hours, vein functionality was tested. Ring segments were fixed by triangles in Krebs-Henseleit buffer. Contractile function was measured after addition of potassium chloride solution (80 mM) and phenylephrine (0.2, 2, or 20 μM). To investigate endothelium-dependent vasorelaxation, 1 μM acetylcholine was added. Of 27 segments, 5 showed endothelium-dependent relaxation. Vasorelaxation continued for up to 48 hours after administration of acetylcholine in University of Wisconsin solution and for up to 24 hours in histidine-tryptophane-ketoglutarate solution. At 48 hours, potassium chloride solution-induced vasocontraction was 17% more effective than phenylephrine in University of Wisconsin solution. University of Wisconsin solution was significantly more effective than histidine-tryptophane-ketoglutarate solution in terms of preservation of phenylephrine (0.2, 2 μM)-induced vasocontraction. Phenylephrine (2 μM)-induced contraction was retained in University of Wisconsin solution after 24 hours by 81% and after 48 hours by 55%, with comparable results in histidine-tryptophane-ketoglutarate solution of only 62% and 34% after 24 and 48 hours. At 48 hours, human saphenous vein transplants had better endothelium and smooth muscle function when preserved in University of Wisconsin solution versus histidine-tryptophane-ketoglutarate solution.
- 20 September 2015
- Published by SAGE Publications in Antioxidants & Redox Signaling
- Vol. 23 (9) , 711-723
Impact of eNOS-Dependent Oxidative Stress on Endothelial Function and Neointima Formation
Aims: Vascular oxidative stress generated by endothelial NO synthase (eNOS) was observed in experimental and clinical cardiovascular disease, but its relative importance for vascular pathologies is unclear. We investigated the impact of eNOS-dependent vascular oxidative stress on endothelial function and on neointimal hyperplasia. Results: A dimer-destabilized mutant of bovine eNOS where cysteine 101 was replaced by alanine was cloned and introduced into an eNOS-deficient mouse strain (eNOS-KO) in an endothelial-specific manner. Destabilization of mutant eNOS in cells and eNOS-KO was confirmed by the reduced dimer/monomer ratio. Purified mutant eNOS and transfected cells generated less citrulline and NO, respectively, while superoxide generation was enhanced. In eNOS-KO, introduction of mutant eNOS caused a 2.3–3.7-fold increase in superoxide and peroxynitrite formation in the aorta and myocardium. This was completely blunted by an NOS inhibitor. Nevertheless, expression of mutant eNOS in eNOS-KO completely restored maximal aortic endothelium-dependent relaxation to acetylcholine. Neointimal hyperplasia induced by carotid binding was much larger in eNOS-KO than in mutant eNOS-KO and C57BL/6, while the latter strains showed comparable hyperplasia. Likewise, vascular remodeling was blunted in eNOS-KO only. Innovation: Our results provide the first in vivo evidence that eNOS-dependent oxidative stress is unlikely to be an initial cause of impaired endothelium-dependent vasodilation and/or a pathologic factor promoting intimal hyperplasia. These findings highlight the importance of other sources of vascular oxidative stress in cardiovascular disease. Conclusion: eNOS-dependent oxidative stress is unlikely to induce functional vascular damage as long as concomitant generation of NO is preserved. This underlines the importance of current and new therapeutic strategies in improving endothelial NO generation. Antioxid. Redox Signal. 23, 711–723.
- 20 September 2015
- Published by SAGE Publications in Antioxidants & Redox Signaling
- Vol. 23 (9) , 711-723
Impact of eNOS-Dependent Oxidative Stress on Endothelial Function and Neointima Formation
Aims: Vascular oxidative stress generated by endothelial NO synthase (eNOS) was observed in experimental and clinical cardiovascular disease, but its relative importance for vascular pathologies is unclear. We investigated the impact of eNOS-dependent vascular oxidative stress on endothelial function and on neointimal hyperplasia. Results: A dimer-destabilized mutant of bovine eNOS where cysteine 101 was replaced by alanine was cloned and introduced into an eNOS-deficient mouse strain (eNOS-KO) in an endothelial-specific manner. Destabilization of mutant eNOS in cells and eNOS-KO was confirmed by the reduced dimer/monomer ratio. Purified mutant eNOS and transfected cells generated less citrulline and NO, respectively, while superoxide generation was enhanced. In eNOS-KO, introduction of mutant eNOS caused a 2.3–3.7-fold increase in superoxide and peroxynitrite formation in the aorta and myocardium. This was completely blunted by an NOS inhibitor. Nevertheless, expression of mutant eNOS in eNOS-KO completely restored maximal aortic endothelium-dependent relaxation to acetylcholine. Neointimal hyperplasia induced by carotid binding was much larger in eNOS-KO than in mutant eNOS-KO and C57BL/6, while the latter strains showed comparable hyperplasia. Likewise, vascular remodeling was blunted in eNOS-KO only. Innovation: Our results provide the first in vivo evidence that eNOS-dependent oxidative stress is unlikely to be an initial cause of impaired endothelium-dependent vasodilation and/or a pathologic factor promoting intimal hyperplasia. These findings highlight the importance of other sources of vascular oxidative stress in cardiovascular disease. Conclusion: eNOS-dependent oxidative stress is unlikely to induce functional vascular damage as long as concomitant generation of NO is preserved. This underlines the importance of current and new therapeutic strategies in improving endothelial NO generation. Antioxid. Redox Signal. 23, 711–723.
- Open Access
Angioedema induced by cardiovascular drugs: new players join old friends
During the last years, two new cardiovascular drug classes, namely inhibitors of DPP IV or neprilysin, have been developed. In both cases, there is clinical evidence for their potential to induce angioedema as known already from blockers of the renin–angiotensin–aldosterone system (RAAS). The majority of angioedema induced by DPP IV inhibitors occurs during concomitant treatment with ACEi and is therefore likely mediated by overactivation of bradykinin type 2 receptors (B2). In striking contrast, the molecular pathways causing angioedema induced by neprilysin inhibitors, that is, sacubitril, are unclear, although a contribution of bradykinin appears likely. Nevertheless, there is no clinical evidence suggesting that inhibition of B2 might relieve the symptoms and/or prevent invasive treatment including coniotomy or tracheotomy in angioedema caused by these drugs. Therefore, the risk of angioedema should always be considered, especially in ambulatory care situations where patients have no rapid access to intensive care.
Open AccessAngioedema induced by cardiovascular drugs: new players join old friends
During the last years, two new cardiovascular drug classes, namely inhibitors of DPP IV or neprilysin, have been developed. In both cases, there is clinical evidence for their potential to induce angioedema as known already from blockers of the renin–angiotensin–aldosterone system (RAAS). The majority of angioedema induced by DPP IV inhibitors occurs during concomitant treatment with ACEi and is therefore likely mediated by overactivation of bradykinin type 2 receptors (B2). In striking contrast, the molecular pathways causing angioedema induced by neprilysin inhibitors, that is, sacubitril, are unclear, although a contribution of bradykinin appears likely. Nevertheless, there is no clinical evidence suggesting that inhibition of B2 might relieve the symptoms and/or prevent invasive treatment including coniotomy or tracheotomy in angioedema caused by these drugs. Therefore, the risk of angioedema should always be considered, especially in ambulatory care situations where patients have no rapid access to intensive care.